Vulnerable ALS neurons reveal molecular warning signs before cell death begins

A new study from the Knight Initiative for Brain Resilience researchers may help explain an enduring mystery about ...
Nature

Network spreading and local biological vulnerability in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that predominantly targets the motor system. Spread of pathology is thought to be driven by both local vulnerability and ...
Nature

Proteomic analysis of brain and spinal cord tissue reveals distinct immune and mitochondrial processes between human and mouse ALS models

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease resulting in the progressive loss of motor neurons in the brain and spine. More than 95% of cases are pathologically ...
EurekAlert!

Why does ALS pathology spread differently among patients?

APOE ε4 was found to be directly associated with the pathological classification of TDP-43 in ALS, whereas Alzheimer’s disease–related proteins, including amyloid-β and tau, showed no significant ...
Medical Xpress

Gene therapy may slow loss of motor function in ALS

Researchers have developed a gene therapy that significantly slowed motor function loss in preclinical models of amyotrophic lateral sclerosis (ALS), offering new hope for treating the devastating ...
Hosted on MSN

Study links an ALS-related protein to DNA repair, cancer, and dementia risk

A protein long studied for its role in amyotrophic lateral sclerosis and frontotemporal dementia now appears to serve a second, equally critical function, safeguarding the integrity of human DNA.
Medical Xpress

Skin-based biomarkers may offer earlier diagnosis for amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes the gradual loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ...
Business Wire

VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology ...

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) ...
insider.si.edu

Ultrastructural pathology : the comparative cellular basis of disease / Norman F. Cheville

PART I: Structural Basis of Cell Injury. 1. Cellular Response to Injury. 2. Cell Death. 3. Cell Defense & Recovery. PART II: Organelle Pathology. 4. Cell Surface and ...